Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study evaluated high-dose oral minoxidil treatment in 57 patients with androgenetic alopecia and found it improved hair density by 10-30% in most cases, but 24.6% experienced adverse effects like hypertrichosis and tachycardia, indicating further research is needed to optimize safety and efficacy.

This study presents the first reported case of cutis verticis gyrata resulting from long-term, high-concentration topical minoxidil use for treating male androgenetic alopecia, highlighting a potential link to insulin-like growth factor effects.

This study found that oral minoxidil was associated with short-term improvements in clinical severity for androgenetic alopecia, whereas oral dutasteride did not show significant early clinical changes in the six-month follow-up.

A newspaper article caused a big rise in oral minoxidil prescriptions for hair loss.

This prospective study reported that 5 mg daily oral low-dose minoxidil over 24 weeks led to a high prevalence of hypertrichosis in 93% of male androgenetic alopecia patients, particularly affecting younger individuals, but generally had minimal impact on patients’ quality of life.

This case report discusses rare but serious cardiac complications, including pericarditis and edema, observed with low-dose oral minoxidil for hair loss, highlighting the need for cautious prescribing, especially in high-risk patients.

This study observed a slight reduction in blood pressure in normotensive patients after taking a 5-mg dose of oral minoxidil, particularly within the first two hours and more so in those with high baseline blood pressure.

This review discusses updated treatment guidelines for alopecia areata in Japan, highlighting new options like corticosteroid pulse therapy, but reports no new clinical results.

This article reviews how various drugs may cause hair loss, stimulate growth, or alter hair characteristics, but reports no new clinical results; drug-induced hair loss is typically reversible.

This review discusses various treatment options for Alopecia Areata, focusing on both medical and psychological approaches, and reports no new clinical results.

This presentation reviews the management of alopecia areata, emphasizing treatment challenges and options, but reports no new clinical results.

This review suggests that low-dose oral minoxidil may be a safe option for treating hair disorders in children, while moderate and high doses may not be safe.

This study reviewed literature on low-dose oral minoxidil as a treatment for hair loss, finding good compliance and tolerability, with mild adverse effects like hypertrichosis, which increase with higher doses.

This letter discusses adverse events related to low-dose oral minoxidil for alopecia, highlighting age-related risks and stressing the importance of contraindication awareness with no new clinical results presented.

In this study of patients with androgenetic alopecia taking off-label low-dose oral minoxidil, adverse events like dizziness/lightheadedness, hypertrichosis, and extremity edema were observed in 14.9% of patients, with females experiencing more adverse events; higher doses increased dizziness risk, leading researchers to recommend cautious dosing approaches.

This consensus statement provides expert guidance on prescribing low-dose oral minoxidil for hair loss, noting a lack of representation of pediatric specialists and highlighting areas for future research.

This study examined the FDA Adverse Event Reporting System database and found significant associations between low-dose oral minoxidil use and adverse events like pericardial effusion, highlighting the need for caution and recommending the use of the lowest effective dose until more safety data are available.

This study found that in healthy young men, oral minoxidil at 5 mg/day led to increased carotid intima-media thickness and vascular aging, suggesting potential cardiovascular side effects at higher doses. A dose-dependent effect was observed, while dutasteride displayed a favorable vascular profile without significant changes.

This study found that high-dose minoxidil, a potassium channel opener, may protect neuronal tissue from damage following transient focal cerebral ischemia in mice.

This study observed that in children who unintentionally consumed high-dose oral minoxidil, 65% developed hypertrichosis, predominantly on the face, and 15% experienced mild systemic side effects.

This study reviewed the publication trends and key findings on alternative therapies for androgenetic alopecia, highlighting the increasing research interest in dutasteride and nontopical minoxidil, while noting a lack of high-quality trials for nontopical minoxidil formulations.

Minoxidil, when used with a diuretic and β-blocking agent, can safely lower blood pressure in most children with severe hypertension due to kidney disease, with minimal side effects.

This case report describes a patient who developed pseudoacromegaly from long-term use of high-dose minoxidil, marking the first such documented case.

This case study describes severe hypertrichosis in a 3-year-old with alopecia areata after unsupervised use of high-dose topical minoxidil, highlighting the need to avoid such practices in children.

This study found that 63.4% of androgenetic alopecia patients showed clinical improvement after 6 months of low-dose oral minoxidil, with patients having low sulfotransferase activity in hair follicles responding more favorably than those with high enzyme activity.

In this case report, a Danish family with monilethrix showed varying symptoms, diagnosed via dermatoscopy, microscopy, and gene sequencing. The study highlights that while no cure exists, oral minoxidil shows promise in a single case, and reducing hair trauma remains key for management.

This review discusses the use of finasteride for androgenetic alopecia and highlights that while it is considered safe, there is concern regarding its sexual side effects, which reverse upon discontinuation.

This review examines the clinical presentation and management strategies for alopecia areata, focusing on pediatric patients, and highlights the need for addressing its psychological impacts; it reports no new clinical findings.

In this study, aralia continentalis extract was observed to promote hair follicle development in mice through anagen progression, with the low dose being more effective than the high dose.

In this retrospective study of patients with androgenetic alopecia, oral minoxidil at doses greater than 5 mg daily improved hair density by 10-30% in most cases, but 24.6% experienced adverse effects, prompting a need for further research on its safety and optimal dosage.